Phosphorylated proteins (relative to total) yielded a significant increase for p-PERK in AD cases compared to non-AD controls (Fig. 2b(i, ii), p < 0.05), which could be attributed to an elevation between low and severe disease stages (Fig. 2b; Braak ≤2 vs. Braak 5–6, p < 0.05). This evidence concerns the gene EIF2AK3 and Alzheimer disease.